Juan Domingo Gispert

Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum

Andréa Lessa Benedet, Marta Milà‐Alomà, Agathe Vrillon et al. · JAMA Neurology · 2021 · 631 citations · Full text

Medicine, Neurology, Neuroscience +17

sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early‐stage Alzheimer's disease and associate with neuronal injury markers

Marc Suárez‐Calvet, Gernot Kleinberger, Miguel Ángel Araque Caballero et al. · EMBO Molecular Medicine · 2016 · 530 citations · Full text

Life Sciences, Neurology, Neuroscience +17

Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected

Marc Suárez‐Calvet, Thomas K. Karikari, Juan Lantero‐Rodriguez et al. · EMBO Molecular Medicine · 2020 · 414 citations · Full text

Life Sciences, Neurology, Neuroscience +17

β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer

Stephan P. Tenbaum, Paloma Ordóñez‐Morán, Isabel Puig et al. · Nature Medicine · 2012 · 400 citations · Full text

Medicine, Cancer Biology, Oncology +17

Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease

Marta Milà‐Alomà, Nicholas J. Ashton, Mahnaz Shekari et al. · Nature Medicine · 2022 · 349 citations · Full text

Life Sciences, Neurology, Neuroscience +17